Home Alzheimer’s Disease Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing Regimen

Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing Regimen

Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab (Keytruda) in patients with metastatic melanoma, was presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020, held from April 27-28, 2020.1

The preliminary pharmacokinetic, efficacy, and safety analyzed from this cohort validated the findings from the model-based assessment, of which a consistent benefit-risk profile was demonstrated for a dosing regimen of 400 mg every 6 weeks compared to the 200 mg (or 2 mg/kg) dosing every 3 weeks. 

“This offers convenience and flexibility to both patients and providers, the need for which is particularly exemplified by the current COVID-19 pandemic,” Mallika Lala, PhD, associate principle scientist for the quantitative pharmacology and pharmacometrics group at Merck, the developer of…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments